My lab group investigates the molecular and cellular basis of Parkinson’s disease and related disorders. We use animal models and patient samples to identify molecular targets for patient stratification, fluid biomarkers and novel therapies. We believe that our research may contribute to understanding the aetiology of Parkinson´s disease and related disorders and ultimately hope to find a breakthrough therapeutic process that could slow down disease progression. We also hope that our neuropharmacology efforts will improve therapies for both motor and non-motor aspects, such as dementia assicoated with Parkinson´s disease. I am also leading a laboratory at the Karolinska Institute, where I am member of the Nobel assembly awarding the annual Nobel Prize in Physiology or Medicine.

Please see my Research Staff Profile for more detail

Key publications:

• Olsson et al., 2019. Delayed Clinical Manifestation of Parkinson’s Disease Among Physically Active: Do Participants in a Long-Distance Ski Race Have a Motor Reserve? Journal of Parkinson's disease.
• Paslawski et al., 2019. α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients PNAS.
• Green et al., 2017. Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease. PNAS.

View all publications

Key collaborators:

• Professor Dag Aarsland, King's College London
• Professor Thomas Perlmann, Karolinska Institutet
• Professor Per E Andren, Uppsala University